Genetic risk assessments in individuals at high risk for inherited breast cancer in the breast oncology care setting

Cancer Control

Volumn 19, Issue 4, 2012, Pages 255-266

  Pal, Tuya ^a   Vadaparampil, Susan T ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BRCA1 PROTEIN; BRCA2 PROTEIN; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MITOMYCIN C; OLAPARIB; PROGESTERONE RECEPTOR; TAMOXIFEN; TAXANE DERIVATIVE;

ARTICLE; ATTITUDE TO PREGNANCY; BREAST CANCER; BREAST RECONSTRUCTION; BREAST SELF EXAMINATION; CANCER PREVENTION; CANCER RADIOTHERAPY; CONFIDENTIALITY; ECHOMAMMOGRAPHY; FEMALE INFERTILITY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; GENETIC COUNSELING; GENETIC RISK; GENETIC SCREENING; GERM LINE; HEALTH CARE DELIVERY; HEALTH CARE ORGANIZATION; HEALTH INSURANCE; HEREDITARY BREAST AND OVARIAN CANCER SYNDROME; HERITABILITY; HIGH RISK PATIENT; HUMAN; MAMMOGRAPHY; MASTECTOMY; MEDICAL DECISION MAKING; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTIAL MASTECTOMY; PATIENT REFERRAL; PATIENT SATISFACTION; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; PRENATAL DIAGNOSIS; QUALITY OF LIFE; RADIATION INJURY; RISK ASSESSMENT; RISK REDUCTION; SALPINGOOOPHORECTOMY; SOCIAL PSYCHOLOGY; TREATMENT PLANNING; TUMOR SUPPRESSOR GENE;

EID: 84866972751     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/107327481201900402     Document Type: Article

References (189)

1. Claus EB, Schildkraut JM, Thompson WD, et al. The genetic attributable risk of breast and ovarian cancer. Cancer. 1996;77(11):2318-2324.
2. Risch HA, McLaughlin JR, Cole DE, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet. 2001;68(3):700-710.
3. Narod SA, Offit K. Prevention and management of hereditary breast cancer. J Clin Oncol. 2005;23(8):1656-1663.
4. Malone KE, Daling JR, Doody DR, et al. Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years. Cancer Res. 2006;66(16):8297-8308.
5. Pal T, Permuth-Wey J, Betts JA, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer. 2005;104(12):2807-2816.
6. Rubin SC, Blackwood MA, Bandera C, et al. BRCA1, BRCA2 and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing. Am J Obstet Gynecol. 1998;178(4):670-677.
7. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72(5):1117-1130.
8. Litton JK, Ready K, Chen H, et al. Earlier age of onset of BRCA mutationrelated cancers in subsequent generations. Cancer. 2012;118(2):321-325.
9. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 2007;25(11):1329-1333.
10. King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003;302(5645):643-646.
11. Moller P, Maehle L, Vabo A, Clark N, Sun P, Narod S. Age-specific incidence rates for breast cancer in carriers of BRCA1 mutations from Norway. Clin Genet. Feb 9.
12. Graeser MK, Engel C, Rhiem K, et al. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2009;27(35):5887-5892.
13. Malone KE, Begg CB, Haile RW, et al. Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2. J Clin Oncol. 2010;28(14):2404-2410.
14. Watson M, Kash KM, Homewood J, et al. Does genetic counseling have any impact on management of breast cancer risk? Genet Test. 2005;9(2):167-174.
15. Roukos DH, Briasoulis E. Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome. Nat Clin Pract Oncol. 2007;4(10):578-590.
16. Weitzel JN, Blazer KR, Macdonald DJ, et al. Genetics, genomics, and cancer risk assessment: state of the art and future directions in the era of personalized medicine. CA Cancer J Clin. 2011 Aug 19. Epub ahead of print.
17. Audeh MW, Penson RT, Friedlander M, et al. Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer. J Clin Oncol. 2009;27:15s (suppl; abstr 5500).
18. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361(2):123-134.
19. Tutt A, Robson M, Garber JE, et al. Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. J Clin Oncol. 2009;27(15 suppl):CRA501. Abstract
20. Genetic/Familial High-Risk Assessment: Breast and Ovarian. NCCN Practice Guidelines. V.1.2012. http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf. Accessed June 21, 2012.
21. Parmigiani G, Berry D, Aguilar O. Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet. 1998;62 (1):145-158.
22. Myriad Genetics, Laboratories and Pharmaceuticals. http://www.myriadtests.com/provider/brca-mutation-prevalence.htm. Accessed June 21, 2012.
23. Euhus DM, Smith KC, Robinson L, et al. Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO. J Natl Cancer Inst. 2002;94(11):844-851.
24. Kang HH, Williams R, Leary J, et al. Evaluation of models to predict BRCA germline mutations. Br J Cancer. 2006;95(7):914-920.
25. Antoniou AC, Hardy R, Walker L, et al. Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics. J Med Genet. 2008;45(7):425-431.
26. Tai YC, Chen S, Parmigiani G, et al. Incorporating tumor immunohistochemical markers in BRCA1 and BRCA2 carrier prediction. Breast Cancer Res. 2008;10(2):401.
27. Biswas S, Tankhiwale N, Blackford A, et al. Assessing the added value of breast tumor markers in genetic risk prediction model BRCAPRO. Breast Cancer Res Treat. 2012;133(1):347-355.
28. Mavaddat N, Rebbeck TR, Lakhani SR, et al. Incorporating tumour pathology information into breast cancer risk prediction algorithms. Breast Cancer Res. 2010;12(3):R28.
29. Rubinstein WS. Hereditary breast cancer: pathobiology, clinical translation, and potential for targeted cancer therapeutics. Fam Cancer. 2008;7(1):83-89.
30. Gronwald J, Tung N, Foulkes WD, et al. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int J Cancer. 2006;118(9):2281-2284.
31. Narod SA, Brunet JS, Ghadirian P, et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet. 2000;356(9245):1876-1881.
32. Pierce LJ, Levin AM, Rebbeck TR, et al. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol. 2006;24(16):2437-2443.
33. Hartmann LC, Sellers TA, Schaid DJ, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst. 2001;93(21):1633-1637.
34. Rebbeck TR, Friebel T, Lynch HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2004;22(6):1055-1062.
35. Meijers-Heijboer H, van Geel B, van Putten WL, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2001;345(3):159-164.
36. van Sprundel TC, Schmidt MK, Rookus MA, et al. Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers. Br J Cancer. 2005;93(3):287-292.
37. Evans DG, Baildam AD, Anderson E, et al. Risk reducing mastectomy: outcomes in 10 European centres. J Med Genet. 2009;46(4):254-258.
38. Heemskerk-Gerritsen BA, Brekelmans CT, Menke-Pluymers MB, et al. Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic. Ann Surg Oncol. 2007;14(12):3335-3344.
39. Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304(9):967-975.
40. Finch A, Beiner M, Lubinski J, et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA. 2006;296(2):185-192.
41. Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst. 2009;101(2):80-87.
42. Eisen A, Lubinski J, Klijn J, et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol. 2005;23(30):7491-7496.
43. Kauff ND, Domchek SM, Friebel TM, et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol. 2008;26(8):1331-1337.
44. Narod SA. BRCA mutations in the management of breast cancer: the state of the art. Nat Rev Clin Oncol. 2010;7(12):702-707.
45. Metcalfe K, Gershman S, Lynch HT, et al. Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer. 2011;104(9):1384-1392.
46. Kurian AW, Sigal BM, Plevritis SK. Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers. J Clin Oncol. 2010;28(2):222-231.
47. Kurian AW, Munoz DF, Rust P, et al. Online tool to guide decisions for BRCA1/2 mutation carriers. J Clin Oncol. 2012;30(5):497-506.
48. Bevers TB, Anderson BO, Bonaccio E, et al. NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis. J Natl Compr Canc Netw. 2009;7(10):1060-1096.
49. Murphy CG, Moynahan ME. BRCA gene structure and function in tumor suppression: a repair-centric perspective. Cancer J. 2010;16(1):39-47.
50. Narod SA, Lubinski J, Ghadirian P, et al. Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Lancet Oncol. 2006;7(5):402-406.
51. Andrieu N, Easton DF, Chang-Claude J, et al. Effect of chest X-rays on the risk of breast cancer among BRCA1/2 mutation carriers in the international BRCA1/2 carrier cohort study: a report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS Collaborators' Group. J Clin Oncol. 2006;24(21):3361-3366.
52. Goldfrank D, Chuai S, Bernstein JL, et al. Effect of mammography on breast cancer risk in women with mutations in BRCA1 or BRCA2. Cancer Epidemiol Biomarkers Prev. 2006;15(11):2311-2313.
53. Warner E, Plewes DB, Hill KA, et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA. 2004;292(11):1317-1325.
54. Leach MO, Boggis CR, Dixon AK, et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet. 2005;365(9473):1769-1778.
55. Kuhl C, Weigel S, Schrading S, et al. Prospective multicenter cohort study to refine management recommendations for women at elevated familial risk of breast cancer: the EVA trial. J Clin Oncol. 2010;28(9):1450-1457.
56. Rijnsburger AJ, Obdeijn IM, Kaas R, et al. BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: long-term followup of the Dutch MRISC Screening Study. J Clin Oncol. 2010;28(36):5265-5273.
57. Weinstein SP, Localio AR, Conant EF, et al. Multimodality screening of high-risk women: a prospective cohort study. J Clin Oncol. 2009;27(36):6124-6128.
58. Sardanelli F, Podo F, Santoro F, et al. Multicenter surveillance of women at high genetic breast cancer risk using mammography, ultrasonography, and contrast-enhanced magnetic resonance imaging (the high breast cancer risk italian 1 study): final results. Invest Radiol. 2011;46(2):94-105.
59. Warner E, Hill K, Causer P, et al. Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging. J Clin Oncol. 2011;29(13):1664-1669.
60. Obdeijn IM, Loo CE, Rijnsburger AJ, et al. Assessment of false-negative cases of breast MR imaging in women with a familial or genetic predisposition. Breast Cancer Res Treat. 2010;119(2):399-407.
61. Shah P, Rosen M, Stopfer J, et al. Prospective study of breast MRI in BRCA1 and BRCA2 mutation carriers: effect of mutation status on cancer incidence. Breast Cancer Res Treat. 2009;118(3):539-546.
62. Gulati AP, Domchek SM. The clinical management of BRCA1 and BRCA2 mutation carriers. Curr Oncol Rep. 2008;10(1):47-53.
63. Nusbaum R, Isaacs C. Management updates for women with a BRCA1 or BRCA2 mutation. Mol Diagn Ther. 2007;11(3):133-144.
64. Smith KL, Isaacs C. Management of women at increased risk for hereditary breast cancer. Breast Dis. 2006;27:51-67.
65. Trainer AH, Lewis CR, Tucker K, et al. The role of BRCA mutation testing in determining breast cancer therapy. Nat Rev Clin Oncol. 2010;7(12):708-717.
66. Metcalfe KA, Birenbaum-Carmeli D, Lubinski J, et al. International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int J Cancer. 2008;122(9):2017-2022.
67. Schwartz MD, Lerman C, Brogan B, et al. Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients. J Clin Oncol. 2004;22(10):1823-1829.
68. Weitzel JN, McCaffrey SM, Nedelcu R, et al. Effect of genetic cancer risk assessment on surgical decisions at breast cancer diagnosis. Arch Surg. 2003;138(12):1323-1328 discussion 1329.
69. Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, Adopted on February 20, 1996. J Clin Oncol. 1996;14(5):1730-1736; discussion 1737-1740.
70. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol. 2003;21(12):2397-2406.
71. Robson ME, Storm CD, Weitzel J, et al. American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol. 2010;28(5):893-901.
72. The American Society of Breast Surgeons. BRCA Genetic Testing for Patients With and Without Breast Cancer. 2006. http://www.breastsurgeons.org/statements/brca.php. Accessed June 27, 2012.
73. Levy DE, Byfield SD, Comstock CB, et al. Underutilization of BRCA1/2 testing to guide breast cancer treatment: Black and Hispanic women particularly at risk. Genet Med. 2011;13(4):349-255.
74. Pierce LJ, Phillips KA, Griffith KA, et al. Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy. Breast Cancer Res Treat. 2010;121(2):389-398.
75. Kirova YM, Savignoni A, Sigal-Zafrani B, et al. Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Longterm results and review of the literature. Breast Cancer Res Treat. 2010;120(1):119-126.
76. Metcalfe K, Lynch HT, Ghadirian P, et al. Risk of ipsilateral breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2011;127(1):287-296.
77. Tung N. Management of women with BRCA mutations: a 41-year-old woman with a BRCA mutation and a recent history of breast cancer. JAMA. 2011;305(21):2211-2220.
78. Mansfield C. Effects of radiation therapy on wound healing after mastectomy. Clin Plast Surg. 1979;6(1):19-26.
79. Vandeweyer E, Deraemaecker R. Radiation therapy after immediate breast reconstruction with implants. Plast Reconstr Surg. 2000;106(1):56-58;discussion 59-60.
80. Daly MB. Tailoring breast cancer treatment to genetic status: the challenges ahead. J Clin Oncol. 2004;22(10):1776-1777.
81. Fedier A, Steiner RA, Schwarz VA, et al. The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells. Int J Oncol. 2003;22(5):1169-1173.
82. Chabalier C, Lamare C, Racca C, et al. BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance. Cell Cycle. 2006;5(9):1001-1007.
83. Byrski T, Gronwald J, Huzarski T, et al. Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers. Breast Cancer Res Treat. 2008;108(2):289-296.
84. Wysocki PJ, Korski K, Lamperska K, et al. Primary resistance to docetaxelbased chemotherapy in metastatic breast cancer patients correlates with a high frequency of BRCA1 mutations. Med Sci Monit. 2008;14(7):SC7-SC10.
85. Bhattacharyya A, Ear US, Koller BH, et al. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem. 2000;275(31):23899-23903.
86. Gronwald J, Byrski T, Huzarski T, et al. Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. J Clin Oncol. 2009;27(15s suppl):502. Abstract.
87. Silver DP, Richardson AL, Eklund AC, et al. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol. 2010;28(7):1145-1153.
88. Bolderson E, Richard DJ, Zhou BB, et al. Recent advances in cancer therapy targeting proteins involved in DNA double-strand break repair. Clin Cancer Res. 2009;15(20):6314-6320.
89. McCabe N, Turner NC, Lord CJ, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 2006;66(16):8109-8115.
90. Tutt AN, Lord CJ, McCabe N, et al. Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer. Cold Spring Harb Symp Quant Biol. 2005;70:139-148.
91. Plummer ER. Inhibition of poly(ADP-ribose) polymerase in cancer. Curr Opin Pharmacol. 2006;6(4):364-368.
92. James CR, Quinn JE, Mullan PB, et al. BRCA1, a potential predictive biomarker in the treatment of breast cancer. Oncologist. 2007;12(2):142-150.
93. Tuma RS. Combining carefully selected drug, patient genetics may lead to total tumor death. J Natl Cancer Inst. 2007;99(20):1505-1506, 1509.
94. Jones C, Plummer ER. PARP inhibitors and cancer therapy: early results and potential applications. Br J Radiol. 2008;81 Spec No 1:S2-5.
95. Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA doublestrand break repair. J Clin Oncol. 2008;26(22):3785-3790.
96. Tutt A, Robson M, Garber JE, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010;376(9737):235-244.
97. Metcalfe KA, Lynch HT, Ghadirian P, et al. The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. Gynecol Oncol. 2005;96(1):222-226.
98. Frost MH, Schaid DJ, Sellers TA, et al. Long-term satisfaction and psychological and social function following bilateral prophylactic mastectomy. JAMA. 2000;284(3):319-324.
99. Metcalfe KA, Semple JL, Narod SA. Satisfaction with breast reconstruction in women with bilateral prophylactic mastectomy: a descriptive study. Plast Reconstr Surg. 2004;114(2):360-366.
100. Stefanek ME, Helzlsouer KJ, Wilcox PM, et al. Predictors of and satisfaction with bilateral prophylactic mastectomy. Prev Med. 1995;24(4):412-419.
101. Frost MH, Slezak JM, Tran NV, et al. Satisfaction after contralateral prophylactic mastectomy: the significance of mastectomy type, reconstructive complications, and body appearance. J Clin Oncol. 2005;23(31):7849-7856.
102. Geiger AM, West CN, Nekhlyudov L, et al. Contentment with quality of life among breast cancer survivors with and without contralateral prophylactic mastectomy. J Clin Oncol. 2006;24(9):1350-1356.
103. Bresser PJ, Seynaeve C, Van Gool AR, et al. Satisfaction with prophylactic mastectomy and breast reconstruction in genetically predisposed women. Plast Reconstr Surg. 2006;117(6):1675-1682discussion 1683-1674.
104. Madalinska JB, Hollenstein J, Bleiker E, et al. Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer. J Clin Oncol. 2005;23(28):6890-6898.
105. Chen CL, Weiss NS, Newcomb P, et al. Hormone replacement therapy in relation to breast cancer. JAMA. 2002;287(6):734-741.
106. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333.
107. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA. 2003;289(24):3243-3253.
108. Eisen A, Lubinski J, Gronwald J, et al. Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. J Natl Cancer Inst. 2008;100(19):1361-1367.
109. Rebbeck TR, Friebel T, Wagner T, et al. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2005;23(31):7804-7810.
110. Anderson GL, Chlebowski RT, Aragaki AK, et al. Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncol. 2012;13(5):476-486.
111. Madalinska JB, Essink-Bot ML, de Koning HJ, et al. Health-related quality of life in patients with screen-detected versus clinically diagnosed prostate cancer preceding primary treatment. Prostate. 2001;46(2):87-97.
112. Partridge AH, Gelber S, Peppercorn J, et al. Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol. 2004;22(20):4174-4183.
113. Lee S, Schover L, Partridge A, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol. 2006;24:2917-2931.
114. The Ethics Committee of the American Society for Reproductive. Medicine fertility preservation and reproduction in cancer patients. Fertil Steril. 2005;83(6):1622-1628.
115. Schover LR, Rybicki LA, Martin BA, et al. Having children after cancer. Cancer. 1999;86(4):697-709.
116. Partridge AH, Gelber S, Peppercorn J, et al. Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol. 2004 2004;22(20):4174-4183.
117. Quinn GP, Vadaparampil ST, Lee JH, et al. Physician referral for fertility preservation in oncology patients: a national study of practice behaviors. J Clin Oncol. 2009;27(35):5952-5957.
118. Staton AD, Kurian AW, Cobb K, et al. Cancer risk reduction and reproductive concerns in female BRCA1/2 mutation carriers. Fam Cancer. 2008;7(2):179-186.
119. Friedman LC, Kramer RM. Reproductive issues for women with BRCA mutations. J Natl Cancer Inst Monogr. 2005;(34):83-86.
120. Smith KR, Ellington L, Chan AY, et al. Fertility intentions following testing for a BRCA1 gene mutation. Cancer Epidemiol Biomarkers Prev. 2004;13(5):733-740.
121. Quinn G, Vadaparampil S, Wilson C, et al. Attitudes of high-risk women toward preimplantation genetic diagnosis. Fertil Steril. 2009;91(6):2361-2368.
122. Ogilvie CM, Braude PR, Scriven PN. Preimplantation genetic diagnosis: an overview. J Histochem Cytochem. 2005;53(3):255-260.
123. Baruch S, Kaufman D, Hudson KL. Genetic testing of embryos: practices and perspectives of US in vitro fertilization clinics. Fertil Steril. 2008;89(5):1053-1058.
124. Dayal MB, Athanasiadis I. Preimplantation Genetic Diagnosis. http://www.emedicine.com/med/topic3520.htm#section~bibliography. Accessed June 28, 2012.
125. Offit K, Kohut K, Clagett B, et al. Cancer genetic testing and assisted reproduction. J Clin Oncol. 2006;24(29):4775-4782.
126. Kim SS, Klemp J, Fabian C. Breast cancer and fertility preservation. Fertil Steril. 2011;95(5):1535-1543.
127. Jacobsen PB, Valdimarsdottier HB, Brown KL, et al. Decision-making about genetic testing among women at familial risk for breast cancer. Psychosom Med. 1997;59(5):459-466.
128. Sussner KM, Jandorf L, Thompson HS, et al. Interest and beliefs about BRCA genetic counseling among at-risk Latinas in New York City. J Genet Couns. 2010;19(3):255-268.
129. Vadaparampil ST, Quinn GP, Dutil J, et al. A pilot study of knowledge and interest of genetic counseling and testing for hereditary breast and ovarian cancer syndrome among Puerto Rican women. J Community Genet. 2011;2(4):211-221.
130. Vadaparampil ST, Quinn GP, Small BJ, et al. A pilot study of hereditary breast and ovarian knowledge among a multiethnic group of Hispanic women with a personal or family history of cancer. Genet Test Mol Biomarkers. 2010;14(1):99-106.
131. Offit K, Groeger E, Turner S, et al. The "duty to warn" a patient's family members about hereditary disease risks. JAMA. 2004;292(12):1469-1473.
132. Finlay E, Stopfer JE, Burlingame E, et al. Factors determining dissemination of results and uptake of genetic testing in families with known BRCA1/2 mutations. Genet Test. 2008;12(1):81-91.
133. Kenen R, Arden-Jones A, Eeles R. Healthy women from suspected hereditary breast and ovarian cancer families: the significant others in their lives. Eur J Cancer Care (Engl). 2004;13(2):169-179.
134. MacDonald DJ, Sarna L, van Servellen G, et al. Selection of family members for communication of cancer risk and barriers to this communication before and after genetic cancer risk assessment. Genet Med. 2007;9(5):275-282.
135. Patenaude AF, Dorval M, DiGianni LS, et al. Sharing BRCA1/2 test results with first-degree relatives: factors predicting who women tell. J Clin Oncol. 2006;24(4):700-706.
136. Wagner Costalas J, Itzen M, Malick J, et al. Communication of BRCA1 and BRCA2 results to at-risk relatives: a cancer risk assessment program's experience. Am J Med Genet C Semin Med Genet. 2003;119C(1):11-18.
137. Dancyger C, Wiseman M, Jacobs C, etc. Communicating BRCA1/2 genetic test results within the family: a qualitative analysis. Psychol Health. 2011;26(8):1018-1035.
138. Loud JT, Weissman NE, Peters JA, et al. Deliberate deceit of family members: a challenge to providers of clinical genetics services. J Clin Oncol. 2006;24(10):1643-1646.
139. Bradbury AR, Dignam JJ, Ibe CN, et al. How often do BRCA mutation carriers tell their young children of the family's risk for cancer? A study of parental disclosure of BRCA mutations to minors and young adults. J Clin Oncol. 2007;25(24):3705-3711.
140. Bradbury AR, Patrick-Miller L, Pawlowski K, et al. Learning of your parent's BRCA mutation during adolescence or early adulthood: a study of offspring experiences. Psychooncology. 2009;18(2):200-208.
141. Sharff ME, Demarco TA, Mays D, et al. Parenting through genetic uncertainty: themes in the disclosure of breast cancer risk information to children. Genet Test Mol Biomarkers. 2012;16(5):376-382.
142. Points to consider: ethical, legal, and psychosocial implications of genetic testing in children and adolescents. American Society of Human Genetics Board of Directors, American College of Medical Genetics Board of Directors. Am J Hum Genet. 1995; 57(5):1233-1241.
143. Robson ME, Storm CD, Weitzel J, et al. American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol. 2010;28(5):893-901.
144. Committee on Bioethics. Ethical issues with genetic testing in pediatrics. Pediatrics. 2001;107(6):1451-1455.
145. Wertz DC, Fanos JH, Reilly PR. Genetic testing for children and adolescents. Who decides? JAMA. 1994;272(11):875-881.
146. Leib JR, Hoodfar E, Haidle JL, et al. The new genetic privacy law. Commun Oncol. 2008;5(6):124-127.
147. Baruch S, Hudson K. Civilian and military genetics: nondiscrimination policy in a post-GINA world. Am J Hum Genet. 2008;83(4):435-444.
148. American Cancer Society. Cancer Facts & Figures 2011. http://www.cancer.org/Research/CancerFactsFigures/index. Accessed June 28, 2012.
149. Vos J, Jansen AM, Menko F, et al. Family communication matters: the impact of telling relatives about unclassified variants and uninformative DNA-test results. Genet Med. 2011;13(4):333-341.
150. Vos J, Menko F, Jansen AM, van Asperen CJ, et al. A whisper-game perspective on the family communication of DNA-test results: a retrospective study on the communication process of BRCA1/2-test results between proband and relatives. Fam Cancer. 2011;10(1):87-96.
151. Vos J, Oosterwijk JC, Gomez-Garcia E, et al. Perceiving cancer-risks and heredity-likelihood in genetic-counseling: how counselees recall and interpret BRCA 1/2-test results. Clin Genet. 2011;79(3):207-218.
152. Berliner JL, Fay AM; Practice Issues Subcommittee of the National Society of Genetic Counselors' Familial Cancer Risk Counseling Special Interest Group. Risk assessment and genetic counseling for hereditary breast and ovarian cancer: recommendations of the National Society of Genetic Counselors. J Genet Couns. 2007;16(3):241-260.
153. Cancer-Related Genetic Testing and Counseling: Workshop Proceedings. National Cancer Policy Forum; Institute of Medicine. National Academy of Sciences, Washington, DC; 2007. http://www.nap.edu/catalog/11971.html. Accessed June 28, 2012.
154. Riley BD, Culver JO, Skrzynia C, et al. Essential elements of genetic cancer risk assessment, counseling, and testing: updated recommendations of the National Society of Genetic Counselors. J Genet Couns. 2012;21(2):151-161.
155. American College of Obstetricians and Gynecologists; ACOG Committee on Practice Bulletins: Gynecology; ACOG Committee on Genetics; Society of Gynecologic Oncologists. ACOG Practice Bulletin No. 103: Hereditary breast and ovarian cancer syndrome. Obstet Gynecol. 2009;113(4):957-966.
156. Oncology Nursing Society. The Role of the Oncology Nurse in Cancer Genetic Counseling. [2009; http://www.ons.org/Publications/Positions/Genetic-Counseling/. Accessed June 28, 2012.
157. Radford C. Understanding the Evolution of and Term "Genetic Counselor": Is the Term Being Used Appropriately in Your Community? Oncol Nurse. 2011;4(5):24-25. http://www.theoncologynurse.com/article/understanding-evolution-and-term-%E2%80%9Cgenetic-counselor%E2%80%9D-term-being-usedappropriately-your-comm.
158. Geier LJ, Mulvey TM, Weitzel JN. Clinical cancer genetics remains a specialized area: how do I get there from here? 2009 Educational Book. American Society of Clinical Oncology. http://www.asco.org/ASCOv2/Home/Education%20 &%20Training/Educational%20Book/PDF%20Files/2009/09EdBk.PractMgmt.03.pdf. Accessed June 29, 2012.
159. Cohen SA, McIlvried D, Schnieders J. A collaborative approach to genetic testing: a community hospital's experience. J Genet Couns. 2009;18(6):530-533.
160. DeMarco TA, Smith KL, Nusbaum RH, et al. Practical aspects of delivering hereditary cancer risk counseling. Semin Oncol. 2007;34(5):369-378.
161. MacDonald DJ, Blazer KR, Weitzel JN. Extending comprehensive cancer center expertise in clinical cancer genetics and genomics to diverse communities: the power of partnership. J Natl Compr Canc Netw. 2010;8(5):615-624.
162. Esserman L, Kaklamani V. Lessons learned from genetic testing. JAMA. 2010;304(9):1011-1012.
163. Brierley KL, Campfield D, Ducaine W, et al. Errors in delivery of cancer genetics services: implications for practice. Conn Med. 2010;74(7):413-423.
164. Lawrence WF, Peshkin BN, Liang W, et al. Cost of genetic counseling and testing for BRCA1 and BRCA2 breast cancer susceptibility mutations. Cancer Epidemiol Biomarkers Prev. 2001;10(5):475-481.
165. Schwartz GF, Hughes KS, Lynch HT, et al. Proceedings of the international consensus conference on breast cancer risk, genetics, & risk management, April, 2007. Cancer. 2008;113(10):2627-2637.
166. Hampel H, Sweet K, Westman JA, et al. Referral for cancer genetics consultation: a review and compilation of risk assessment criteria. J Med Genet. 2004;41(2):81-91.
167. Weitzel JN. Genetic cancer risk assessment. Putting it all together. Cancer. 1999;86(11 suppl):2483-2492.
168. Ganz PA, Kwan L, Somerfield MR, et al. The role of prevention in oncology practice: results from a 2004 survey of American Society of Clinical Oncology members. J Clin Oncol. 2006;24(18):2948-2957.
169. McPherson E, Zaleski C, Benishek K, et al. Clinical genetics provider realtime workflow study. Genet Med. 2008;10(9):699-706.
170. Bernhardt BA, Tumpson JE, Pyeritz RE. The economics of clinical genetics services. IV. Financial impact of outpatient genetic services on an academic institution. Am J Hum Genet. 1992;50(1):84-91.
171. Vadaparampil ST, Quinn GP, Miree CA, et al. Recall of and reactions to a surgeon referral letter for BRCA genetic counseling among high-risk breast cancer patients. Ann Surg Oncol. 2009;16(7):1973-1981.
172. Vadaparampil ST, Quinn GP, Brzosowicz J, et al. Experiences of genetic counseling for BRCA1/2 among recently diagnosed breast cancer patients: a qualitative inquiry. J Psychosoc Oncol. 2008;26(4):33-52.
173. Vadaparampil ST, Quinn GP, Lee JH, et al. Satisfaction with physician recommendation for and information about genetic counseling among breast cancer patients. Breast J. 2011;17(1):79-82.
174. Acheson LS, Stange KC, Zyzanski S. Clinical genetics issues encountered by family physicians. Genet Med. 2005;7(7):501-508.
175. Vig HS, Armstrong J, Egleston BL, et al. Cancer genetic risk assessment and referral patterns in primary care. Genet Test Mol Biomarkers. 2009;13(6):735-741.
176. (ASCO) ASoCO. Cancer Genetics and Cancer Predisposition Testing. 2nd ed. Alexandria, VA: American Society of Clinical Oncology Publishing; 2004.
177. National Cancer Policy Forum, Institute of Medicine. Cancer-Related Genetic Testing and Counseling: Workshop Proceedings. The National Academies Press; 2007.
178. Daly MB, Axilbund JE, Buys S, et al. Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Canc Netw. 2010;8(5):562-594.
179. Calzone KA, Jenkins J, Masny A. Core competencies in cancer genetics for advanced practice oncology nurses. Oncol Nurs Forum. 2002;29(9):1327-1333.
180. Genetic testing in adoption. The American Society of Human Genetics Social Issues Committee and The American College of Medical Genetics Social, Ethical, and Legal Issues Committee. Am J Hum Genet. 2000;66(3):761-767.
181. Kolb SE, Aguilar MC, Dinenberg M, Kaye CI. Genetics education for primary care providers in community health settings. J Community Health. 1999;24(1):45-59.
182. Korf BR. Medical education in the 'postgenomic era'. Postgrad Med. 2000;108(3):15-18.
183. Peterson SK, Rieger PT, Marani SK, et al. Oncology nurses' knowledge, practice, and educational needs regarding cancer genetics. Am J Med Genet. 2001;98(1):3-12.
184. Reynolds PP, Benkendorf JL. Genes and generalists: why we need professionals with added competencies. West J Med. 1999;171(5-6):375-379.
185. Schwartz MD, Valdimarsdottir HB, DeMarco TA, et al. Randomized trial of a decision aid for BRCA1/BRCA2 mutation carriers: impact on measures of decision making and satisfaction. Health Psychol. 2009;28(1):11-19.
186. Ozanne EM, Loberg A, Hughes S, et al. Identification and management of women at high risk for hereditary breast/ovarian cancer syndrome. Breast J. 2009;15(2):155-162.
187. Drohan B, Ozanne EM, Hughes KS. Electronic health records and the management of women at high risk of hereditary breast and ovarian cancer. Breast J. 2009;15 suppl 1:S46-S55.
188. Drohan B, Roche CA, Cusack JC Jr, et al. Hereditary breast and ovarian cancer and other hereditary syndromes: using technology to identify carriers. Ann Surg Oncol. 2012;19(6):1732-1737.
189. Zon RT, Goss E, Vogel VG, et al. American Society of Clinical Oncology policy statement: the role of the oncologist in cancer prevention and risk assessment. J Clin Oncol. 2009;27(6):986-993.